Article

bizjournals.com on 2018-10-25 17:01

Biogen analysts pounce on 'thin' Alzheimer's trial data

Biogen

Related news

Biogen analysts pounce on 'thin' Alzheimer's trial data bizjournals.com
Biogen stock gains on leaked Alzheimer's drug data bizjournals.com
San Diego
Analysts wary of Biogen's strategy as earnings, Alzheimer's data loom bizjournals.com
Biogen data reignites debate over Alzheimer's cause as investors back off (Video)bizjournals.com
Mayo Clinic , Cambridge
BBiogen, Eisai's Alzheimer's Data Confirm Benefit, But Questions Loom2 min read barrons.com
MBiogen shares tumble on Alzheimer's candidate data marketwatch.com
Biogen trial drug shows promise in fight against Alzheimer's The Japan Times
Arizona , Phoenix , Switzerland , United States
Biogen pays California biotech $350M upfront for Alzheimer's gene therapy bizjournals.com
California
WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
Biogen says new drug shows promise in combating Alzheimer's metro.us
Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference bizjournals.com
Biogen shares soar as FDA reviewers support Alzheimer's drug Sydney Morning Herald
Wall Street , Massachusetts , Cambridge
Biogen buoyed despite Alzheimer's drug's new, more restrictive label bizjournals.com
Biogen to cease production of controversial Alzheimer's drug POLITICO
Biogen reworks Alzheimer's drug pacts in bullish move bizjournals.com
In reversal, Biogen to file for approval of Alzheimer's drug bizjournals.com
Biogen doubles down on Alzheimer's with new collaboration deal bizjournals.com
Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug bizjournals.com